Devicare, a Spanish medical device company, receives €3M
09/05/2017
Diego Gutiérrez
Devicare, a Spanish medical device company, receives €3M
Devicare, founded in 2012 in Barcelona, is a company specialising in innovative medical devices for the home care of the chronic patient, under the concept of Remote Patient Monitoring (RPM).
About Devicare

Devicare is a technology company that develops devices for the home management of chronically ill patients. Founded in 2012, since January it has been marketing Lit Control in Spain, a device for monitoring urine pH, and food supplements that help balance it, allowing patients to self-manage urinary diseases such as kidney stones, overactive bladder or cystitis and prevent relapses.

In December 2016, Devicare closed its first contract for licensing its products in Mexico, with the firm InnovaSalud and is currently in advanced negotiations with other distributors to enter Italy, Germany, Canada and other Latin American countries.

Devicare already raised a small round of €850,000 in June last year led by Emesa Corporación Empresarial, Emilio Cuatrecasas' investment company, which controls 5% of the company.

In addition, Devicare has also recently secured a loan to  270,000 (ENISA). In this context, since its foundation, Devicare has already raised a total of €4.5 million in funding.

Devicare receives a €3M round of funding

In this second round of investment of €3M, several family offices and corporate partners with high knowledge in the world of health have entered the company, such as Juan Knuth (Palex Medical), the Gaya family (Eladiet), the Xiol family (Peroxfarma), and the Serra family (Boyser), among others.

Según palabras del propio Rosendo Garganta, fundador y CEO de Devicare «Este perfil de inversores es sin duda de gran aportación estratégica para el crecimiento de nuestra empresa”

The market for remote patient monitoring

The global market for Remote Patient Monitoring , is a market with a lot of potential, in 2016 it grew by 44% and it is estimated that the number of monitored patients will reach 50.2 million in four years. Investors have bet heavily on this sector in the last year.

Other posts that may interest you

Inkemia, which is listed on the Mab, carries out a capital increase, opens a subsidiary and prepares to jump to the English Mab.

Sanitas buys Helthia to enter the world of digitalisation

acquisitions-en-biotecnologia-de-dispositivos-medicos/»>Listado de acquisitions en biotecnología de dispositivos médicos

If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

 

Lastest news

Latest transactions in the Cybersecurity sector

El sector de la ciberseguridad ha sido testigo de una importante oleada de adquisiciones estratégicas en los últimos meses, a medida que las empresas tratan de ampliar sus capacidades y hacer frente a la creciente demanda de una sólida protección digital. Cinco...

Latest transactions in the Consumer Software sector

El sector del Consumer software ha experimentado recientemente una dinámica oleada de adquisiciones que pone de relieve su evolución hacia la mejora de la participación de los usuarios y la ampliación de los servicios digitales. Entre las operaciones más destacadas...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

Request for information

If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

Or if you prefer, call us at:

+34 946 42 41 42